Will Amgen say “Eosinophilic”?
Amgen said “Eosinophilic” 6 times on its Nov 3, 2026 call (FY26 Q3), and on 6 of its last 8 calls: 1, 0, 1, 2, 2, 0, 1, 6 times. As of Nov 11, 2026, Amgen said “Eosinophilic” on the only call with a settled Kalshi mention market so far, on Nov 3, 2026. Parrot’s p for the next listing is 76% (n=1, from settlement history blended with transcripts), not a forecast.
- Last 10
- 1/1Last 10 settled, oldest to newest: yes
- Streak
- said last time
- Counts
- company speakers + operator
- Market
- 73¢ Kalshi (may be delayed)
Where it was said
quotes of at most 25 words; select an appearanceAmgen
Eosinophilic
- Probability
- 76% · n=1
- Settled
- 1/1 (100%)
- Last calls
- said in 6 of 8
Next listing counts: company speakers + operator
Counts: company speakers + operator
6 counted (6 in prepared remarks, 0 in Q&A).
…we are working to establish it as the cornerstone therapy, TEZSPIRE in eosinophilic esophagitis, an area with significant unmet need, and dazodalibep in Sjögren's disease,…
…in the need for surgery. More recently, positive phase III results in eosinophilic esophagitis, or EoE, demonstrated meaningful improvements in key measures of disease activity…
Counts: company speakers + operator (not listed here; the usual rule)
1 counted (1 in prepared remarks, 0 in Q&A).
…where epithelial-driven inflammation plays a key role. Our phase III study in eosinophilic esophagitis, or EoE, is expected to complete in the second half of…
Counts: company speakers + operator (not listed here; the usual rule)
2 counted (2 in prepared remarks, 0 in Q&A).
…continues to advance, with ongoing studies in chronic obstructive pulmonary disease and eosinophilic esophagitis. Where we expect study completion in the second half of this…
…reduced the need for surgery in this population reinforcing its value in eosinophilic disease. TESSPIRE is now the leading therapy for new-to-brand patients amongst allergists…
Every settled listing
newest first · 1 shown| Date | Listed as | Venue | Result | Our count |
|---|---|---|---|---|
| Nov 3, 2026 | Eosinophilic |  Kalshi | Yes | 6 |
Questions
- How many times did Amgen say “Eosinophilic” on its last earnings call?
- Amgen said “Eosinophilic” 6 times on its Nov 3, 2026 call (FY26 Q3), and on 6 of its last 8 calls: 1, 0, 1, 2, 2, 0, 1, 6 times.
- How often does Amgen say “Eosinophilic”?
- As of Nov 11, 2026, Amgen said “Eosinophilic” on the only call with a settled Kalshi mention market so far, on Nov 3, 2026.
- What is the probability Amgen says “Eosinophilic” next time?
- 76%, from settlement history blended with transcripts (n=1). It is a base rate from history, not a forecast and not advice.
- Who has to say it for the market to count?
- Under the next market's rule: company speakers + operator.
Cite parrot.markets, “Amgen: ‘Eosinophilic’ mention history”, as of Nov 11, 2026, https://parrot.markets/earnings/AMGN/words/eosinophilic (CC BY 4.0)
Agents: this page as TSV at /api/v1/word?entity=amgen&word=eosinophilic · quotes: /api/v1/quotes?entity=amgen&word=… · columnar JSON in #parrot-data · llms.txt · MCP